Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This safeguard is a feature of responsible medically supervised weight loss , not a bureaucratic burden
Pharma is innovating to hit even more targets The latest article I saw about the work being done in this class is a study in mice looking at a quintuple agonist (5 different targets!) I almost never write about mice studies because of how preliminary they are and how unlikely a finding in mice is to ever translate into anything useful in humans, but because of the success weve already seen of this drug class as well as the way that hitting more pathways seems to increase efficacy, I thought this was research worth highlighting
Participants were randomized to placebo or retatrutide at 1 mg, 4 mg (dose-escalation), 4 mg (no escalation), 8 mg (escalation), 8 mg (no escalation), or 12 mg (escalation) for 48 weeks, following a slow titration protocol
Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial
Dramatically underpriced retatrutide often signals missing or fabricated third-party testing, inconsistent manufacturing quality, or identity substitution
School of Pharmacy, Pharmacy Australia Centre of Excellence, the University of Queensland, Woolloongabba, Queensland 4102, Australia
